Latest Partnerships News

ABx Group has made significant strides in its rare earths and clean fluorine chemical projects, receiving high-purity product validation and advancing pilot plant construction, while progressing bauxite mining approvals across multiple states.

Strategic Energy Resources (ASX:SER) has locked in a $6 million joint venture with Sumitomo for its Bulimba Gold Project, secured $400,000 in government grants for drilling, and completed capital consolidation, positioning itself for a busy exploration season in Queensland.

Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.

Prairie Lithium has moved Pad #1 from groundwork to active building construction, backed by SaskPower's powerline installation and a binding Hydro Lithium offtake agreement that includes a A$10 million equipment contribution. First production is targeted for Q4 2026.

Aureka Limited extends its Victorian gold resource ambitions with strong drilling results at Irvine and Comstock, backed by fresh geophysical data and secured tenure.

Terrain Minerals has completed major drilling campaigns across its flagship Lightning gold project and critical metals targets, setting the stage for a maiden resource estimate and advancing metallurgical studies on gallium and rare earth elements.

Zimi Limited posted 14% revenue growth and landed its biggest project order to date with Homecorp, while slashing operating costs and launching an AI sales agent.

TrivarX has made significant strides in preparing its Stabl-Im stable isotope imaging platform for Phase 1 clinical trials, backed by strengthened leadership and a solid cash reserve of $2.91 million.

Marquee Resources has significantly increased its Mt Clement inferred antimony resource and is advancing drilling and strategic partnerships to develop its flagship project.

Pointerra Limited delivered a 214% jump in Q3 FY26 customer receipts to A$2.2 million, driven by milestone invoicing and new Tier 1 utility contracts, edging closer to operating cashflow breakeven.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Green360 Technologies has kicked off commercial production of its low-carbon Eco-Clay cement alternative through a capital-light tolling agreement with Calix, while securing federal grant funding and a $4.5 million placement to fuel growth.